Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 68Breast 20Plasma cell 9Thoracic 4Gastrointestinal 4Tumor-Agnostic 3Other hematologic neoplasm 3Lymphoid 3Genitourinary 3Sarcoma 2Other solid neoplasm 2Head & Neck 2Dermatologic 2NET 1Endocrine 1Classical hematology 1CNS 1

Conditions

Solid Tumors 2

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × liposomal doxorubicin × Other solid neoplasm × Clear all
NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

AstraZeneca

Phase 1 Terminated
44 enrolled
Other solid neoplasm

Solid Tumors

NCT01214668 2019-01-04

Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
31 enrolled 17 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡